AbbVie’s strategic acquisition of ImmunoGen for $10.1 billion in November 2023 is already showing promising results. The deal, which included the antibody-drug conjugate (ADC) Elahere, has yielded positive outcomes in a recent Phase 2 study.

According to Endpoints, Elahere achieved the primary endpoint in a single-arm Phase 2 trial, demonstrating a 51.9% objective response rate as a monotherapy in pretreated patients with FR-alpha high platinum-sensitive ovarian cancer. The median duration of response was an impressive 8.25 months.

These encouraging data further validate AbbVie’s decision to acquire ImmunoGen and its portfolio, particularly Elahere. The drug has already received approval for the treatment of select patients with epithelial, ovarian, fallopian, or peritoneal cancer.

The acquisition of ImmunoGen aligns with AbbVie’s strategy to expand its presence in the growing ADC market. The company had been actively seeking opportunities in this space, and the ImmunoGen deal seems to be paying off.

As Elahere continues to show efficacy in treating various types of ovarian cancer, AbbVie’s investment in the drug and the ADC technology behind it appears to be a wise move. The company’s commitment to enhancing its oncology pipeline is evident, and the success of Elahere in this mid-stage trial is a testament to the potential of ADCs in the fight against cancer.

Read more on Endpoints

This article was originally published on iBIO NewsBrief. Gain a head start on your day with iBIO NewsBrief. Subscribe to receive top industry headlines delivered straight to your inbox.

X